Unknown statusInterventionalPhase 1Last updated Apr 21, 2022

Ribociclib and Spartalizumab in R/M HNSCC

Ribociclib and Spartalizumab for Head and Neck Squamous Cell Carcinoma, a Phase I Study With Expansion Cohort (RISE-HN)

Overview

ClinicalTrials.gov ID: NCT04213404
Lead Sponsor: National Taiwan University HospitalOTHER
Brief Summary: This study examines the safety and efficacy of ribociclib (CDK 4/6 inhibitors) and spartalizumab (anti-PD1) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Study Type: Interventional

Status

Study Record Dates

NCT04000529Terminated

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

NCT03294694Terminated

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

NCT05996107Recruiting

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

NCT05628870Recruiting

A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer

NCT04802876Active, not recruiting

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

NCT05296746Active, not recruiting

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer